



Clinical trial results:

A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis

Summary

| | |
|--------------------------|-------------------------|
| EudraCT number | 2012-002011-26 |
| Trial protocol | SK HU CZ GB EE DE BG PL |
| Global end of trial date | 30 March 2015 |

Results information

| | |
|--------------------------------|---------------|
| Result version number | v1 (current) |
| This version publication date | 31 March 2016 |
| First version publication date | 31 March 2016 |

Trial information

Trial identification

| | |
|-----------------------|----------|
| Sponsor protocol code | GP15-302 |
|-----------------------|----------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01891864 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Sandoz |
| Sponsor organisation address | Industriestrasse 25, Holzkirchen, Germany, 83607 |
| Public contact | Strategic Planning Biopharma Clinical Development, Sandoz, 0049 8024 / 476 - 0, biopharma.clinicaltrials@sandoz.com |
| Scientific contact | Strategic Planning Biopharma Clinical Development, Sandoz, 0049 8024 / 476 - 0, biopharma.clinicaltrials@sandoz.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|-----------------|
| Analysis stage | Final |
| Date of interim/final analysis | 19 January 2016 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 24 June 2014 |
| Global end of trial reached? | Yes |
| Global end of trial date | 30 March 2015 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The aim of this study was to demonstrate equivalence in efficacy (primarily based on PASI 75 response rate) and similarity in the safety profile of GP2015 and Enbrel® (EU-licensed) in patients with moderate to severe chronic plaque-type psoriasis and to evaluate the effects of repeated switching between GP2015 and Enbrel® on efficacy, overall safety and immunogenicity.

Protection of trial subjects:

This trial was designed, conducted and reported in accordance with the international Conference on Harmonization (ICH) Guidelines for Good Clinical Practice (GCP), applicable local regulations (including European Directive 2001/20/EC), and following the ethical principles laid down in the Declaration of Helsinki. Specific ICH adopted and other relevant international guidelines and recommendations were taken into account as far as meaningfully possible, as long as they did not conflict with applicable UK law.

Safety assessments included adverse events (AEs), vital signs, 12-lead ECG parameters, clinical laboratory, immunogenicity, physical examination and other parameters considered relevant for the safety assessment.

Background therapy: -

Evidence for comparator: -

| | |
|---|--------------|
| Actual start date of recruitment | 24 June 2013 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | Poland: 190 |
| Country: Number of subjects enrolled | Romania: 33 |
| Country: Number of subjects enrolled | Bulgaria: 21 |
| Country: Number of subjects enrolled | Germany: 29 |
| Country: Number of subjects enrolled | Hungary: 21 |
| Country: Number of subjects enrolled | Estonia: 81 |
| Country: Number of subjects enrolled | Russian Federation: 17 |
| Country: Number of subjects enrolled | Ukraine: 42 |
| Country: Number of subjects enrolled | Czech Republic: 41 |
| Country: Number of subjects enrolled | South Africa: 5 |
| Country: Number of subjects enrolled | United Kingdom: 14 |
| Country: Number of subjects enrolled | Slovakia: 37 |
| Worldwide total number of subjects | 531 |
| EEA total number of subjects | 467 |

Notes:

| Subjects enrolled per age group | |
|---|-----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 503 |
| From 65 to 84 years | 28 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

This was a multicenter, randomized, double-blind, confirmatory safety and efficacy study. In total 774 patients were screened to randomize 531 patients with moderate to severe chronic plaque-type psoriasis. Patients were randomized at 71 study centers in 12 countries.

Pre-assignment

Screening details:

Prior to baseline (Treatment Day 1, Visit 2) patients were to undergo an eligibility assessment period of at least 2 weeks and up to a maximum of 4 weeks duration.

Period 1

| | |
|------------------------------|--|
| Period 1 title | Treatment period 1 |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor, Data analyst, Assessor |

Blinding implementation details:

All treatment assignments were blinded and concealed from patients and investigator site staff. A patient randomization list will be produced by the IRT provider using a validated system. Each patient randomization number is associated with one of the treatment arms.

Arms

| | |
|------------------------------|--------|
| Are arms mutually exclusive? | Yes |
| Arm title | GP2015 |

Arm description:

GP2015 50 mg subcutaneous (s.c.) injection of study drug until Week12

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | Etanercept |
| Investigational medicinal product code | GP2015 |
| Other name | |
| Pharmaceutical forms | Solution for injection in pre-filled syringe |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

GP2015 50 mg subcutaneous (s.c.) injection of study drug until Week12

The total number of IMP injections is 24 during Treatment Period 1 (two per week from Treatment Day 1 to Week 12).

| | |
|------------------|--------|
| Arm title | Enbrel |
|------------------|--------|

Arm description:

Enbrel 50 mg subcutaneous (s.c.) injection of study drug until Week12

| | |
|--|---|
| Arm type | Active comparator |
| Investigational medicinal product name | Etanercept |
| Investigational medicinal product code | Enbrel |
| Other name | |
| Pharmaceutical forms | Solution for injection/infusion in pre-filled syringe |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Enbrel 50 mg subcutaneous (s.c.) injection of study drug until Week12

The total number of IMP injections is 24 during Treatment Period 1 (two per week from Treatment Day 1 to Week 12).

| Number of subjects in period 1 | GP2015 | Enbrel |
|---------------------------------------|--------|--------|
| Started | 264 | 267 |
| Completed | 256 | 255 |
| Not completed | 8 | 12 |
| Adverse event, serious fatal | - | 1 |
| Consent withdrawn by subject | 2 | 5 |
| Physician decision | - | 1 |
| Adverse event, non-fatal | 4 | 4 |
| Lost to follow-up | 1 | - |
| Protocol deviation | 1 | 1 |

Period 2

| | |
|------------------------------|--|
| Period 2 title | Treatment period 2 |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor, Data analyst |

Blinding implementation details:

All treatment assignments were blinded and concealed from patients and investigator site staff. A patient randomization list will be produced by the IRT provider using a validated system. Each patient randomization number is associated with one of the treatment arms.

Arms

| | |
|------------------------------|------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | GP2015 continued |

Arm description:

GP2015 50 mg subcutaneous (s.c.) injection of study drug from week 13 until Week 30 in patients who had achieved at least a PASI50 response at Week 12

| | |
|--|---|
| Arm type | Experimental |
| Investigational medicinal product name | GP2015 |
| Investigational medicinal product code | GP2015 |
| Other name | |
| Pharmaceutical forms | Solution for infusion in pre-filled syringe |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

GP2015 50 mg subcutaneous (s.c.) injection of study drug from week 13 until Week 30. The total number of IMP injections is 18 during Treatment Period 2 (one per week from Week 13 to Week 30)

| | |
|------------------|------------------|
| Arm title | Enbrel continued |
|------------------|------------------|

Arm description:

Enbrel 50 mg subcutaneous (s.c.) injection of study drug from week 13 until Week 30 in patients who had achieved at least a PASI50 response at Week 12

| | |
|----------|-------------------|
| Arm type | Active comparator |
|----------|-------------------|

| | |
|--|---|
| Investigational medicinal product name | Etanercept |
| Investigational medicinal product code | Enbrel |
| Other name | |
| Pharmaceutical forms | Solution for infusion in pre-filled syringe |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Enbrel 50 mg subcutaneous (s.c.) injection of study drug from week 13 until Week 30.
The total number of IMP injections is 18 during Treatment Period 2 (one per week from Week 13 to Week 30).

| | |
|------------------|-----------------|
| Arm title | GP2015 switched |
|------------------|-----------------|

Arm description:

GP2015 50 mg subcutaneous (s.c.) injection of study drug from week 13 until Week 30 in patients who had achieved at least a PASI50 response at Week 12

| | |
|--|---|
| Arm type | Experimental |
| Investigational medicinal product name | GP2015 in period 1/Enbrel/GP 2015/Enbrel |
| Investigational medicinal product code | GP2015/Enbrel |
| Other name | |
| Pharmaceutical forms | Solution for injection/infusion in pre-filled syringe |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

GP2015/Enbrel 50 mg subcutaneous (s.c.) injection of study drug until Week 30. Three periods of 6 weeks alternating between Enbrel/GP2015/Enbrel. The total number of IMP injections is 18 during Treatment Period 2 (one per week from Treatment Week 13 to Week 30)

| | |
|------------------|-----------------|
| Arm title | Enbrel switched |
|------------------|-----------------|

Arm description:

Enbrel/GP2015 50 mg subcutaneous (s.c.) injection of study drug from week 13 until Week 30 in patients who had achieved at least a PASI50 response at Week 30

| | |
|--|---|
| Arm type | Active comparator |
| Investigational medicinal product name | Enbrel in period 1/GP2015/Enbrel/GP2015 |
| Investigational medicinal product code | Enbrel/GP2015 |
| Other name | |
| Pharmaceutical forms | Solution for injection/infusion in pre-filled syringe |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Enbrel/GP2015 50 mg subcutaneous (s.c.) injection of study drug until Week 30. Three periods of 6 weeks alternating between GP2015/Enbrel/GP2015. The total number of IMP injections is 18 during Treatment Period 2 (one per week from Treatment Week 13 to Week 30)

| Number of subjects in period 2^[1] | GP2015 continued | Enbrel continued | GP2015 switched |
|---|------------------|------------------|-----------------|
| Started | 150 | 151 | 100 |
| Completed | 143 | 142 | 96 |
| Not completed | 7 | 9 | 4 |
| Consent withdrawn by subject | 3 | 4 | 1 |
| Physician decision | 1 | - | - |
| Adverse event, non-fatal | 1 | 2 | - |
| site termination | 1 | 2 | - |
| termination of site | - | - | 2 |

| | | | |
|--------------------|---|---|---|
| Lack of efficacy | 1 | - | 1 |
| Protocol deviation | - | 1 | - |

| Number of subjects in period 2^[1] | Enbrel switched |
|---|-----------------|
| Started | 96 |
| Completed | 91 |
| Not completed | 5 |
| Consent withdrawn by subject | 1 |
| Physician decision | - |
| Adverse event, non-fatal | 4 |
| site termination | - |
| termination of site | - |
| Lack of efficacy | - |
| Protocol deviation | - |

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Only patients with a PASI50 response at 12 weeks -continuing treatment- were included in treatment period 2.

Period 3

| | |
|------------------------------|--|
| Period 3 title | Extension period |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor, Data analyst, Assessor |

Blinding implementation details:

All treatment assignments were blinded and concealed from patients and investigator site staff. A patient randomization list will be produced by the IRT provider using a validated system. Each patient randomization number is associated with one of the treatment arms.

Arms

| | |
|------------------------------|------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | GP2015 continued |

Arm description:

GP2015 50 mg subcutaneous (s.c.) injection of study drug from week 31 until Week 52 in patients who had completed treatment period 2.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | GP2015 |
| Investigational medicinal product code | GP2015 |
| Other name | |
| Pharmaceutical forms | Solution for injection in pre-filled syringe |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

GP2015 50 mg subcutaneous (s.c.) injection of study drug from week 31 until Week 52 in patients who had completed treatment period 2.

The total number of IMP injections is 22 during the Extension Period.

| | |
|------------------|------------------|
| Arm title | Enbrel continued |
|------------------|------------------|

Arm description:

Enbrel 50 mg subcutaneous (s.c.) injection of study drug from week 31 until Week 52 in patients who had completed treatment period 2.

| | |
|--|--|
| Arm type | Active comparator |
| Investigational medicinal product name | Enbrel |
| Investigational medicinal product code | Enbrel |
| Other name | |
| Pharmaceutical forms | Solution for injection in pre-filled syringe |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Enbrel 50 mg subcutaneous (s.c.) injection of study drug from week 31 until Week 52 in patients who had completed treatment period 2.

The total number of IMP injections is 22 during the Extension Period

| | |
|------------------|-----------------|
| Arm title | GP2015 switched |
|------------------|-----------------|

Arm description:

Enbrel 50 mg subcutaneous (s.c.) injection of study drug from week 31 until Week 52 in patients who had completed treatment period 2.

| | |
|--|--|
| Arm type | Active comparator |
| Investigational medicinal product name | Enbrel |
| Investigational medicinal product code | Enbrel |
| Other name | |
| Pharmaceutical forms | Solution for injection in pre-filled syringe |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Enbrel 50 mg subcutaneous (s.c.) injection of study drug from week 31 until Week 52 in patients who had completed treatment period 2.

The total number of IMP injections is 22 during the Extension Period. They continued the drug last used in treatment period 2.

| | |
|------------------|-----------------|
| Arm title | Enbrel switched |
|------------------|-----------------|

Arm description:

GP2015 50 mg subcutaneous (s.c.) injection of study drug from week 31 until Week 52 in patients who had completed treatment period 2.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | GP2015 |
| Investigational medicinal product code | GP2015 |
| Other name | |
| Pharmaceutical forms | Solution for injection in pre-filled syringe |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

GP2015 50 mg subcutaneous (s.c.) injection of study drug from week 31 until Week 52 in patients who had completed treatment period 2.

The total number of IMP injections is 22 during the Extension Period. The last drug used in treatment period 2 was continued in the extension period.

| Number of subjects in period 3^[2] | GP2015 continued | Enbrel continued | GP2015 switched |
|---|------------------|------------------|-----------------|
| Started | 140 | 142 | 95 |
| Completed | 132 | 137 | 88 |
| Not completed | 8 | 5 | 7 |
| Consent withdrawn by subject | 1 | 2 | 4 |

| | | | |
|--------------------------|---|---|---|
| Adverse event, non-fatal | 4 | 2 | 2 |
| Pregnancy | 1 | - | - |
| Lost to follow-up | 2 | - | - |
| Lack of efficacy | - | 1 | 1 |

| Number of subjects in period 3 ^[2] | Enbrel switched |
|--|-----------------|
| | |
| Started | 90 |
| Completed | 90 |
| Not completed | 0 |
| Consent withdrawn by subject | - |
| Adverse event, non-fatal | - |
| Pregnancy | - |
| Lost to follow-up | - |
| Lack of efficacy | - |

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Only patients completing treatment period 2 and continuing in the extension period participated

Baseline characteristics

Reporting groups

| | |
|---|--------|
| Reporting group title | GP2015 |
| Reporting group description: GP2015 50 mg subcutaneous (s.c.) injection of study drug until Week12 | |
| Reporting group title | Enbrel |
| Reporting group description: Enbrel 50 mg subcutaneous (s.c.) injection of study drug until Week12 | |

| Reporting group values | GP2015 | Enbrel | Total |
|-------------------------|----------|----------|-------|
| Number of subjects | 264 | 267 | 531 |
| Age categorical | | | |
| Units: Subjects | | | |
| Age 18-64 | 254 | 249 | 503 |
| Age 65-85 | 10 | 18 | 28 |
| Age continuous | | | |
| Age treatment period 1 | | | |
| Units: years | | | |
| arithmetic mean | 42.1 | 42.7 | |
| standard deviation | ± 12.29 | ± 12.86 | - |
| Gender categorical | | | |
| Male and female numbers | | | |
| Units: Subjects | | | |
| Female | 107 | 95 | 202 |
| Male | 157 | 172 | 329 |
| Weight | | | |
| Weight | | | |
| Units: kg | | | |
| arithmetic mean | 86.3 | 85.9 | |
| standard deviation | ± 21.12 | ± 18.72 | - |
| BMI | | | |
| BMI | | | |
| Units: kg/m2 | | | |
| arithmetic mean | 28.561 | 28.0458 | |
| standard deviation | ± 6.0953 | ± 5.4632 | - |

End points

End points reporting groups

| | |
|---|------------------|
| Reporting group title | GP2015 |
| Reporting group description: GP2015 50 mg subcutaneous (s.c.) injection of study drug until Week12 | |
| Reporting group title | Enbrel |
| Reporting group description: Enbrel 50 mg subcutaneous (s.c.) injection of study drug until Week12 | |
| Reporting group title | GP2015 continued |
| Reporting group description: GP2015 50 mg subcutaneous (s.c.) injection of study drug from week 13 until Week 30 in patients who had achieved at least a PASI50 response at Week 12 | |
| Reporting group title | Enbrel continued |
| Reporting group description: Enbrel 50 mg subcutaneous (s.c.) injection of study drug from week 13 until Week 30 in patients who had achieved at least a PASI50 response at Week 12 | |
| Reporting group title | GP2015 switched |
| Reporting group description: GP2015 50 mg subcutaneous (s.c.) injection of study drug from week 13 until Week 30 in patients who had achieved at least a PASI50 response at Week 12 | |
| Reporting group title | Enbrel switched |
| Reporting group description: Enbrel/GP2015 50 mg subcutaneous (s.c.) injection of study drug from week 13 until Week 30 in patients who had achieved at least a PASI50 response at Week 30 | |
| Reporting group title | GP2015 continued |
| Reporting group description: GP2015 50 mg subcutaneous (s.c.) injection of study drug from week 31 until Week 52 in patients who had completed treatment period 2. | |
| Reporting group title | Enbrel continued |
| Reporting group description: Enbrel 50 mg subcutaneous (s.c.) injection of study drug from week 31 until Week 52 in patients who had completed treatment period 2. | |
| Reporting group title | GP2015 switched |
| Reporting group description: Enbrel 50 mg subcutaneous (s.c.) injection of study drug from week 31 until Week 52 in patients who had completed treatment period 2. | |
| Reporting group title | Enbrel switched |
| Reporting group description: GP2015 50 mg subcutaneous (s.c.) injection of study drug from week 31 until Week 52 in patients who had completed treatment period 2. | |

Primary: PASI 75 response rate at Week 12 between GP2015 and Enbrel

| | |
|---|--|
| End point title | PASI 75 response rate at Week 12 between GP2015 and Enbrel |
| End point description: The 95% CI for the PASI 75 response rate differences at Week12 between GP2015 and Enbrel. | |
| End point type | Primary |
| End point timeframe: The PASI 75 response reate was determined at 12 weeks. | |

| End point values | GP2015 | Enbrel | | |
|-----------------------------|--------------------|--------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 239 ^[1] | 241 ^[2] | | |
| Units: percentage | | | | |
| number (not applicable) | 73.4 | 75.7 | | |

Notes:

[1] - PPS

[2] - PPS

Statistical analyses

| Statistical analysis title | 95% CI of PASI 75 response difference at week12 |
|-----------------------------------|---|
|-----------------------------------|---|

Statistical analysis description:

PASI 75 response rate (proportion of patients showing at least a 75% improvement in PASI) after the first 12 weeks of treatment (Treatment Period 1) was the primary endpoint to assess equivalence between GP2015 and Enbrel®. Therapeutic equivalence in terms of PASI75 could be concluded if the exact 95% confidence interval for the difference in the PASI75 rates is completely contained within the interval [-18%; 18%]. A logistic regression model was to be employed.

| | |
|---|-------------------------------------|
| Comparison groups | GP2015 v Enbrel |
| Number of subjects included in analysis | 480 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence ^[3] |
| P-value | < 0.025 |
| Method | Regression, Logistic |
| Parameter estimate | 95% CI of response rate differences |
| Point estimate | -2.3 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -9.85 |
| upper limit | 5.3 |

Notes:

[3] - The analysis of the primary variable was based on the PPS.

Secondary: % change from baseline in PASI score up to Week12

| | |
|-----------------|---|
| End point title | % change from baseline in PASI score up to Week12 |
|-----------------|---|

End point description:

The key sec. efficacy endpoint in TP1 was the % change from baseline in PASI score up to Week12. Two approaches (MMRM and ATE approach) were employed in order to calculate 2-sided 95% CIs for the difference between the treatment groups.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Percent change in PASI between baseline to week 12.

| End point values | GP2015 | Enbrel | | |
|------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 239 | 241 | | |
| Units: percentage difference | | | | |
| number (not applicable) | -56.11 | -55.48 | | |

Statistical analyses

| Statistical analysis title | MMRM method percentage change PASI response 0-12 w |
|---|--|
| Statistical analysis description: | |
| A MMRM (Mixed Model Repeated Method) was performed on the percentage change from baseline in PASI score from baseline to Week 12. Therapeutic equivalence in terms of the % change from baseline in PASI score was to be determined if the 95% CI for the difference between GP2015 and Enbrel was contained within the interval [-15%; 15%]. | |
| Comparison groups | GP2015 v Enbrel |
| Number of subjects included in analysis | 480 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence |
| P-value | < 0.025 |
| Method | Mixed models analysis |
| Parameter estimate | Mean difference (final values) |
| Point estimate | -0.64 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.474 |
| upper limit | 2.204 |

| Statistical analysis title | ATE of PASI response from baseline to week 12 |
|--|---|
| Statistical analysis description: | |
| The mean averaged treatment effect (ATE) of percent change from baseline in PASI score up to week 12 was derived for each patient and analyzed using an ANCOVA approach. Therapeutic equivalence in terms of the % change from baseline in PASI score was to be determined if the 95% CI for the difference between GP2015 and Enbrel was contained within the interval [-15%; 15%]. | |
| Comparison groups | GP2015 v Enbrel |
| Number of subjects included in analysis | 480 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence |
| P-value | < 0.025 |
| Method | ANCOVA |
| Parameter estimate | Mean difference (final values) |
| Point estimate | -0.88 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.61 |
| upper limit | 1.845 |

Secondary: % Change from baseline in PASI score at the end of treatment period 2

| | |
|-----------------|---|
| End point title | % Change from baseline in PASI score at the end of treatment period 2 |
|-----------------|---|

End point description:

Percentage change in PASI score at the end of treatment period 2 at 30 weeks.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Between week 0 and week 30

| End point values | GP2015 continued | Enbrel continued | GP2015 switched | Enbrel switched |
|--------------------------------------|---------------------|---------------------|---------------------|---------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 137 ^[4] | 129 ^[5] | 90 ^[6] | 88 ^[7] |
| Units: percentage | | | | |
| arithmetic mean (standard deviation) | -88.955 (± 12.3509) | -88.885 (± 12.3666) | -88.287 (± 13.5151) | -88.517 (± 13.9095) |

Notes:

[4] - PPS

[5] - PPS

[6] - PPS

[7] - PPS

Statistical analyses

No statistical analyses for this end point

Secondary: % Change from baseline in PASI score at the end of the extension period

| | |
|-----------------|---|
| End point title | % Change from baseline in PASI score at the end of the extension period |
|-----------------|---|

End point description:

Percentage change in PASI score between baseline and end of the extension period.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Between baseline and 52 weeks

| End point values | GP2015 continued | Enbrel continued | GP2015 switched | Enbrel switched |
|--------------------------------------|---------------------|---------------------|---------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 126 ^[8] | 128 ^[9] | 85 ^[10] | 87 ^[11] |
| Units: percentage | | | | |
| arithmetic mean (standard deviation) | -87.833 (± 16.8661) | -86.597 (± 15.9226) | -85.574 (± 19.4098) | -88.527 (± 15.752) |

Notes:

[8] - PPS

[9] - PPS

[10] - PPS

[11] - PPS

Statistical analyses

No statistical analyses for this end point

Other pre-specified: PASI 75 response rate at the end of treatment period 2

| | |
|-----------------|--|
| End point title | PASI 75 response rate at the end of treatment period 2 |
|-----------------|--|

End point description:

PASI 75 response rate at 30 weeks.

| | |
|----------------|---------------------|
| End point type | Other pre-specified |
|----------------|---------------------|

End point timeframe:

At week 30

| End point values | GP2015 continued | Enbrel continued | GP2015 switched | Enbrel switched |
|-----------------------------|------------------|------------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 119 | 112 | 78 | 76 |
| Units: percentage | | | | |
| number (not applicable) | 86.9 | 86.8 | 86.7 | 86.4 |

Statistical analyses

No statistical analyses for this end point

Other pre-specified: PASI 75 response rate at the end of the extension period

| | |
|-----------------|--|
| End point title | PASI 75 response rate at the end of the extension period |
|-----------------|--|

End point description:

PASI 75 response rate at 52 weeks.

| | |
|----------------|---------------------|
| End point type | Other pre-specified |
|----------------|---------------------|

End point timeframe:

At week 52

| End point values | GP2015 continued | Enbrel continued | GP2015 switched | Enbrel switched |
|-----------------------------|---------------------|---------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 108 | 104 | 71 | 74 |
| Units: percentage | | | | |
| number (not applicable) | 85.7 | 81.3 | 83.5 | 85.1 |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

To ensure patient safety, every SAE/AE, regardless of suspected causality, occurring after the patient has provided informed consent and until 30 days after the patient has stopped study participation

Adverse event reporting additional description:

The occurrence of AEs should be sought by non-directive questioning of the patient at each visit during the study. AEs also may be detected when they are volunteered by the patient during or between visits or through physical examination, laboratory test, or other assessments.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 17.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|------------------|
| Reporting group title | GP2015 continued |
|-----------------------|------------------|

Reporting group description:

GP2015 50 mg subcutaneous (s.c.) injection of study drug until Week52

| | |
|-----------------------|-----------------|
| Reporting group title | Enbrel switched |
|-----------------------|-----------------|

Reporting group description:

GP2015 50 mg subcutaneous (s.c.) injection of study drug until Week52

| | |
|-----------------------|-----------------|
| Reporting group title | GP2015 switched |
|-----------------------|-----------------|

Reporting group description:

Enbrel 50 mg subcutaneous (s.c.) injection of study drug until Week52

| | |
|-----------------------|------------------|
| Reporting group title | Enbrel continued |
|-----------------------|------------------|

Reporting group description:

Enbrel 50 mg subcutaneous (s.c.) injection of study drug until Week52

| Serious adverse events | GP2015 continued | Enbrel switched | GP2015 switched |
|---|------------------|-----------------|-------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 10 / 164 (6.10%) | 6 / 96 (6.25%) | 11 / 100 (11.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Malignant melanoma in situ | | | |
| subjects affected / exposed | 1 / 164 (0.61%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Squamous cell carcinoma of the cervix | | | |

| | | | |
|--|-----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Thrombophlebitis | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 1 / 96 (1.04%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| Abortion spontaneous | | | |
| subjects affected / exposed | 1 / 164 (0.61%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| Milk allergy | | | |
| subjects affected / exposed | 1 / 164 (0.61%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Respiratory failure | | | |
| subjects affected / exposed | 1 / 164 (0.61%) | 0 / 96 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary sarcoidosis | | | |

| | | | |
|---|-------------------------------------|----------------|-----------------|
| subjects affected / exposed | 0 / 164 (0.00%) | 1 / 96 (1.04%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 1 / 164 (0.61%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Meniscus injury | | | |
| subjects affected / exposed | 1 / 164 (0.61%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper limb fracture | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower limb fracture | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Cardiopulmonary failure | Additional description: Fatal event | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Cerebral infarction | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 1 / 96 (1.04%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Multiple sclerosis | | | |

| | | | |
|---|-----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders | | | |
| Retinal detachment | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 1 / 96 (1.04%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Umbilical hernia | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mesenteric vascular insufficiency | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Drug-induced liver injury | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholelithiasis | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Psoriasis | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| renal failure acute | | | |

| | | | |
|--|-----------------|----------------|-----------------|
| subjects affected / exposed | 1 / 164 (0.61%) | 0 / 96 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Psoriatic arthropathy | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Appendicitis | | | |
| subjects affected / exposed | 1 / 164 (0.61%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 164 (0.61%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Brain abscess | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| lobar pneumonia | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 1 / 164 (0.61%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diverticulitis | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 1 / 96 (1.04%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|----------------|-----------------|
| Tonsillitis | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 1 / 96 (1.04%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eczema infected | | | |
| subjects affected / exposed | 1 / 164 (0.61%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Acid-base balance disorder mixed | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|------------------|--|--|
| Serious adverse events | Enbrel continued | | |
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 7 / 171 (4.09%) | | |
| number of deaths (all causes) | 1 | | |
| number of deaths resulting from adverse events | 0 | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Malignant melanoma in situ | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Squamous cell carcinoma of the cervix | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vascular disorders | | | |
| Thrombophlebitis | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pregnancy, puerperium and perinatal conditions | | | |

| | | | |
|---|-----------------------------------|--|--|
| Abortion spontaneous subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 0 / 171 (0.00%) 0 / 0 0 / 0 | | |
| General disorders and administration site conditions Fatigue subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 0 / 171 (0.00%) 0 / 0 0 / 0 | | |
| Immune system disorders Milk allergy subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 0 / 171 (0.00%) 0 / 0 0 / 0 | | |
| Respiratory, thoracic and mediastinal disorders Respiratory failure subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 0 / 171 (0.00%) 0 / 0 0 / 0 | | |
| Epistaxis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 1 / 171 (0.58%) 0 / 1 0 / 0 | | |
| Pulmonary sarcoidosis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 0 / 171 (0.00%) 0 / 0 0 / 0 | | |
| Chronic obstructive pulmonary disease subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 0 / 171 (0.00%) 0 / 0 0 / 0 | | |
| Injury, poisoning and procedural complications Meniscus injury | | | |

| | | | |
|---|-------------------------------------|--|--|
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Upper limb fracture | | | |
| subjects affected / exposed | 1 / 171 (0.58%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Lower limb fracture | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiac disorders | | | |
| Cardiopulmonary failure | Additional description: Fatal event | | |
| subjects affected / exposed | 1 / 171 (0.58%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Nervous system disorders | | | |
| Cerebral infarction | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Multiple sclerosis | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Eye disorders | | | |
| Retinal detachment | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal disorders | | | |
| Umbilical hernia | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Mesenteric vascular insufficiency | | | |
| subjects affected / exposed | 1 / 171 (0.58%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatobiliary disorders | | | |
| Drug-induced liver injury | | | |
| subjects affected / exposed | 1 / 171 (0.58%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cholelithiasis | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Skin and subcutaneous tissue disorders | | | |
| Psoriasis | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal and urinary disorders | | | |
| renal failure acute | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Psoriatic arthropathy | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Appendicitis | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 171 (0.58%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Brain abscess | | | |
| subjects affected / exposed | 1 / 171 (0.58%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| lobar pneumonia | | | |
| subjects affected / exposed | 1 / 171 (0.58%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Sepsis | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diverticulitis | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Tonsillitis | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Eczema infected | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Metabolism and nutrition disorders | | | |
| Acid-base balance disorder mixed | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 1 %

| Non-serious adverse events | GP2015 continued | Enbrel switched | GP2015 switched |
|---|--------------------|------------------|-------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 134 / 164 (81.71%) | 89 / 96 (92.71%) | 99 / 100 (99.00%) |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 5 / 164 (3.05%) | 2 / 96 (2.08%) | 3 / 100 (3.00%) |
| occurrences (all) | 5 | 2 | 3 |
| General disorders and administration site conditions | | | |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 2 / 96 (2.08%) | 2 / 100 (2.00%) |
| occurrences (all) | 0 | 2 | 2 |
| Fatigue | | | |
| subjects affected / exposed | 1 / 164 (0.61%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 3 / 164 (1.83%) | 0 / 96 (0.00%) | 3 / 100 (3.00%) |
| occurrences (all) | 3 | 0 | 3 |
| oropharyngeal pain | | | |
| subjects affected / exposed | 3 / 164 (1.83%) | 1 / 96 (1.04%) | 3 / 100 (3.00%) |
| occurrences (all) | 3 | 1 | 3 |
| Investigations | | | |
| Blood pressure increased | | | |
| subjects affected / exposed | 2 / 164 (1.22%) | 0 / 96 (0.00%) | 4 / 100 (4.00%) |
| occurrences (all) | 2 | 0 | 4 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 6 / 164 (3.66%) | 2 / 96 (2.08%) | 1 / 100 (1.00%) |
| occurrences (all) | 6 | 2 | 1 |
| Aspartate aminotransferase increased | | | |

| | | | |
|---|----------------------|---------------------|----------------------|
| subjects affected / exposed occurrences (all) | 5 / 164 (3.05%) 5 | 2 / 96 (2.08%) 2 | 1 / 100 (1.00%) 1 |
| Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all) | 6 / 164 (3.66%) 6 | 0 / 96 (0.00%) 0 | 3 / 100 (3.00%) 3 |
| Weight increased subjects affected / exposed occurrences (all) | 2 / 164 (1.22%) 2 | 0 / 96 (0.00%) 0 | 3 / 100 (3.00%) 3 |
| Blood uric acid increased subjects affected / exposed occurrences (all) | 3 / 164 (1.83%) 3 | 0 / 96 (0.00%) 0 | 0 / 100 (0.00%) 0 |
| Nervous system disorders Sciatica subjects affected / exposed occurrences (all) | 0 / 164 (0.00%) 0 | 2 / 96 (2.08%) 2 | 0 / 100 (0.00%) 0 |
| Headache subjects affected / exposed occurrences (all) | 3 / 164 (1.83%) 3 | 3 / 96 (3.13%) 3 | 4 / 100 (4.00%) 4 |
| Somnolence subjects affected / exposed occurrences (all) | 0 / 164 (0.00%) 0 | 0 / 96 (0.00%) 0 | 2 / 100 (2.00%) 2 |
| Blood and lymphatic system disorders Lymph node pain subjects affected / exposed occurrences (all) | 0 / 164 (0.00%) 0 | 1 / 96 (1.04%) 1 | 1 / 100 (1.00%) 1 |
| Lymphadenopathy subjects affected / exposed occurrences (all) | 4 / 164 (2.44%) 4 | 1 / 96 (1.04%) 1 | 1 / 100 (1.00%) 1 |
| Eye disorders Eye haemorrhage subjects affected / exposed occurrences (all) | 0 / 164 (0.00%) 0 | 1 / 96 (1.04%) 1 | 1 / 100 (1.00%) 1 |
| Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all) | 4 / 164 (2.44%) 4 | 3 / 96 (3.13%) 3 | 1 / 100 (1.00%) 1 |

| | | | |
|---|----------------------|---------------------|----------------------|
| Abdominal pain upper subjects affected / exposed occurrences (all) | 3 / 164 (1.83%) 3 | 0 / 96 (0.00%) 0 | 0 / 100 (0.00%) 0 |
| Nausea subjects affected / exposed occurrences (all) | 0 / 164 (0.00%) 0 | 2 / 96 (2.08%) 2 | 1 / 100 (1.00%) 1 |
| Gastritis subjects affected / exposed occurrences (all) | 0 / 164 (0.00%) 0 | 2 / 96 (2.08%) 2 | 2 / 100 (2.00%) 2 |
| Toothache subjects affected / exposed occurrences (all) | 0 / 164 (0.00%) 0 | 3 / 96 (3.13%) 3 | 0 / 100 (0.00%) 0 |
| Dental caries subjects affected / exposed occurrences (all) | 0 / 164 (0.00%) 0 | 2 / 96 (2.08%) 2 | 0 / 100 (0.00%) 0 |
| Hepatobiliary disorders Hepatic steatosis subjects affected / exposed occurrences (all) | 0 / 164 (0.00%) 0 | 1 / 96 (1.04%) 1 | 1 / 100 (1.00%) 1 |
| Hepatitis alcoholic subjects affected / exposed occurrences (all) | 0 / 164 (0.00%) 0 | 2 / 96 (2.08%) 2 | 0 / 100 (0.00%) 0 |
| Skin and subcutaneous tissue disorders Psoriasis subjects affected / exposed occurrences (all) | 0 / 164 (0.00%) 0 | 1 / 96 (1.04%) 1 | 2 / 100 (2.00%) 2 |
| Pruritus subjects affected / exposed occurrences (all) | 2 / 164 (1.22%) 2 | 0 / 96 (0.00%) 0 | 0 / 100 (0.00%) 0 |
| Dermatitis psoriasiform subjects affected / exposed occurrences (all) | 0 / 164 (0.00%) 0 | 1 / 96 (1.04%) 1 | 1 / 100 (1.00%) 1 |
| Dermatitis allergic subjects affected / exposed occurrences (all) | 3 / 164 (1.83%) 3 | 0 / 96 (0.00%) 0 | 0 / 100 (0.00%) 0 |
| Pruritis generalized | | | |

| | | | |
|---|-------------------------|------------------------|-------------------------|
| subjects affected / exposed occurrences (all) | 0 / 164 (0.00%) 0 | 1 / 96 (1.04%) 1 | 1 / 100 (1.00%) 1 |
| Renal and urinary disorders Haematuria subjects affected / exposed occurrences (all) | 3 / 164 (1.83%) 3 | 1 / 96 (1.04%) 1 | 1 / 100 (1.00%) 1 |
| Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) | 5 / 164 (3.05%) 5 | 5 / 96 (5.21%) 5 | 3 / 100 (3.00%) 3 |
| Back pain subjects affected / exposed occurrences (all) | 7 / 164 (4.27%) 7 | 4 / 96 (4.17%) 4 | 2 / 100 (2.00%) 2 |
| Spinal pain subjects affected / exposed occurrences (all) | 2 / 164 (1.22%) 2 | 0 / 96 (0.00%) 0 | 0 / 100 (0.00%) 0 |
| Pain in extremity subjects affected / exposed occurrences (all) | 0 / 164 (0.00%) 0 | 1 / 96 (1.04%) 1 | 2 / 100 (2.00%) 2 |
| Musculoskeletal pain subjects affected / exposed occurrences (all) | 0 / 164 (0.00%) 0 | 1 / 96 (1.04%) 1 | 1 / 100 (1.00%) 1 |
| Myalgia subjects affected / exposed occurrences (all) | 0 / 164 (0.00%) 0 | 1 / 96 (1.04%) 1 | 1 / 100 (1.00%) 1 |
| Osteoarthritis subjects affected / exposed occurrences (all) | 0 / 164 (0.00%) 0 | 1 / 96 (1.04%) 1 | 1 / 100 (1.00%) 1 |
| Infections and infestations Pharyngitis subjects affected / exposed occurrences (all) | 7 / 164 (4.27%) 7 | 3 / 96 (3.13%) 3 | 5 / 100 (5.00%) 5 |
| Nasopharyngitis subjects affected / exposed occurrences (all) | 20 / 164 (12.20%) 20 | 10 / 96 (10.42%) 10 | 14 / 100 (14.00%) 14 |
| Viral upper respiratory tract infection | | | |

| | | | |
|-----------------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed | 5 / 164 (3.05%) | 8 / 96 (8.33%) | 4 / 100 (4.00%) |
| occurrences (all) | 5 | 8 | 4 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 4 / 164 (2.44%) | 1 / 96 (1.04%) | 4 / 100 (4.00%) |
| occurrences (all) | 4 | 1 | 4 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 4 / 164 (2.44%) | 3 / 96 (3.13%) | 1 / 100 (1.00%) |
| occurrences (all) | 4 | 3 | 1 |
| Rhinitis | | | |
| subjects affected / exposed | 2 / 164 (1.22%) | 3 / 96 (3.13%) | 1 / 100 (1.00%) |
| occurrences (all) | 2 | 3 | 1 |
| Bronchitis | | | |
| subjects affected / exposed | 4 / 164 (2.44%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Tonsillitis | | | |
| subjects affected / exposed | 5 / 164 (3.05%) | 1 / 96 (1.04%) | 1 / 100 (1.00%) |
| occurrences (all) | 5 | 1 | 1 |
| Influenza | | | |
| subjects affected / exposed | 2 / 164 (1.22%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 1 / 96 (1.04%) | 2 / 100 (2.00%) |
| occurrences (all) | 0 | 1 | 2 |
| Urinary tract infection | | | |
| subjects affected / exposed | 2 / 164 (1.22%) | 1 / 96 (1.04%) | 2 / 100 (2.00%) |
| occurrences (all) | 2 | 1 | 2 |
| Viral infection | | | |
| subjects affected / exposed | 3 / 164 (1.83%) | 1 / 96 (1.04%) | 1 / 100 (1.00%) |
| occurrences (all) | 3 | 1 | 1 |
| Cystitis | | | |
| subjects affected / exposed | 3 / 164 (1.83%) | 0 / 96 (0.00%) | 0 / 100 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 1 / 96 (1.04%) | 1 / 100 (1.00%) |
| occurrences (all) | 0 | 1 | 1 |
| Folliculitis | | | |

| | | | |
|---|-----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 2 / 100 (2.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Herpes simplex | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 2 / 100 (2.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Pyelonephritis | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 2 / 100 (2.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Upper respiratory tract infection bacterial | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 1 / 96 (1.04%) | 1 / 100 (1.00%) |
| occurrences (all) | 0 | 1 | 1 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 1 / 96 (1.04%) | 1 / 100 (1.00%) |
| occurrences (all) | 0 | 1 | 1 |
| Metabolism and nutrition disorders | | | |
| Diabetes mellitus | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 2 / 96 (2.08%) | 1 / 100 (1.00%) |
| occurrences (all) | 0 | 2 | 1 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 0 / 164 (0.00%) | 0 / 96 (0.00%) | 2 / 100 (2.00%) |
| occurrences (all) | 0 | 0 | 2 |

| | | | |
|---|--------------------|--|--|
| Non-serious adverse events | Enbrel continued | | |
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 118 / 171 (69.01%) | | |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 7 / 171 (4.09%) | | |
| occurrences (all) | 7 | | |
| General disorders and administration site conditions | | | |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences (all) | 0 | | |
| Fatigue | | | |
| subjects affected / exposed | 3 / 171 (1.75%) | | |
| occurrences (all) | 3 | | |

| | | | |
|---|-----------------|--|--|
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 2 / 171 (1.17%) | | |
| occurrences (all) | 2 | | |
| oropharyngeal pain | | | |
| subjects affected / exposed | 2 / 171 (1.17%) | | |
| occurrences (all) | 2 | | |
| Investigations | | | |
| Blood pressure increased | | | |
| subjects affected / exposed | 2 / 171 (1.17%) | | |
| occurrences (all) | 2 | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 2 / 171 (1.17%) | | |
| occurrences (all) | 2 | | |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 1 / 171 (0.58%) | | |
| occurrences (all) | 1 | | |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences (all) | 0 | | |
| Weight increased | | | |
| subjects affected / exposed | 4 / 171 (2.34%) | | |
| occurrences (all) | 4 | | |
| Blood uric acid increased | | | |
| subjects affected / exposed | 2 / 171 (1.17%) | | |
| occurrences (all) | 2 | | |
| Nervous system disorders | | | |
| Sciatica | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences (all) | 0 | | |
| Headache | | | |
| subjects affected / exposed | 8 / 171 (4.68%) | | |
| occurrences (all) | 8 | | |
| Somnolence | | | |

| | | | |
|---|----------------------|--|--|
| subjects affected / exposed occurrences (all) | 0 / 171 (0.00%) 0 | | |
| Blood and lymphatic system disorders Lymph node pain subjects affected / exposed occurrences (all) | 0 / 171 (0.00%) 0 | | |
| Lymphadenopathy subjects affected / exposed occurrences (all) | 0 / 171 (0.00%) 0 | | |
| Eye disorders Eye haemorrhage subjects affected / exposed occurrences (all) | 0 / 171 (0.00%) 0 | | |
| Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all) | 2 / 171 (1.17%) 2 | | |
| Abdominal pain upper subjects affected / exposed occurrences (all) | 3 / 171 (1.75%) 3 | | |
| Nausea subjects affected / exposed occurrences (all) | 0 / 171 (0.00%) 0 | | |
| Gastritis subjects affected / exposed occurrences (all) | 4 / 171 (2.34%) 4 | | |
| Toothache subjects affected / exposed occurrences (all) | 0 / 171 (0.00%) 0 | | |
| Dental caries subjects affected / exposed occurrences (all) | 0 / 171 (0.00%) 0 | | |
| Hepatobiliary disorders Hepatic steatosis subjects affected / exposed occurrences (all) | 0 / 171 (0.00%) 0 | | |
| Hepatitis alcoholic | | | |

| | | | |
|--|----------------------|--|--|
| subjects affected / exposed occurrences (all) | 0 / 171 (0.00%) 0 | | |
| Skin and subcutaneous tissue disorders | | | |
| Psoriasis | | | |
| subjects affected / exposed | 5 / 171 (2.92%) | | |
| occurrences (all) | 5 | | |
| Pruritus | | | |
| subjects affected / exposed | 4 / 171 (2.34%) | | |
| occurrences (all) | 4 | | |
| Dermatitis psoriasiform | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences (all) | 0 | | |
| Dermatitis allergic | | | |
| subjects affected / exposed | 1 / 171 (0.58%) | | |
| occurrences (all) | 1 | | |
| Pruritis generalized | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences (all) | 0 | | |
| Renal and urinary disorders | | | |
| Haematuria | | | |
| subjects affected / exposed | 1 / 171 (0.58%) | | |
| occurrences (all) | 1 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 7 / 171 (4.09%) | | |
| occurrences (all) | 7 | | |
| Back pain | | | |
| subjects affected / exposed | 3 / 171 (1.75%) | | |
| occurrences (all) | 3 | | |
| Spinal pain | | | |
| subjects affected / exposed | 2 / 171 (1.17%) | | |
| occurrences (all) | 2 | | |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences (all) | 0 | | |
| Musculoskeletal pain | | | |

| | | | |
|---|------------------|--|--|
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences (all) | 0 | | |
| Myalgia | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences (all) | 0 | | |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences (all) | 0 | | |
| Infections and infestations | | | |
| Pharyngitis | | | |
| subjects affected / exposed | 10 / 171 (5.85%) | | |
| occurrences (all) | 10 | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 17 / 171 (9.94%) | | |
| occurrences (all) | 17 | | |
| Viral upper respiratory tract infection | | | |
| subjects affected / exposed | 6 / 171 (3.51%) | | |
| occurrences (all) | 6 | | |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 2 / 171 (1.17%) | | |
| occurrences (all) | 2 | | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 5 / 171 (2.92%) | | |
| occurrences (all) | 5 | | |
| Rhinitis | | | |
| subjects affected / exposed | 4 / 171 (2.34%) | | |
| occurrences (all) | 4 | | |
| Bronchitis | | | |
| subjects affected / exposed | 3 / 171 (1.75%) | | |
| occurrences (all) | 3 | | |
| Tonsillitis | | | |
| subjects affected / exposed | 1 / 171 (0.58%) | | |
| occurrences (all) | 1 | | |
| Influenza | | | |
| subjects affected / exposed | 3 / 171 (1.75%) | | |
| occurrences (all) | 3 | | |

| | | | |
|--|-----------------|--|--|
| Oral herpes | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences (all) | 0 | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 3 / 171 (1.75%) | | |
| occurrences (all) | 3 | | |
| Viral infection | | | |
| subjects affected / exposed | 2 / 171 (1.17%) | | |
| occurrences (all) | 2 | | |
| Cystitis | | | |
| subjects affected / exposed | 1 / 171 (0.58%) | | |
| occurrences (all) | 1 | | |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences (all) | 0 | | |
| Folliculitis | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences (all) | 0 | | |
| Herpes simplex | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pyelonephritis | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences (all) | 0 | | |
| Upper respiratory tract infection bacterial | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences (all) | 0 | | |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences (all) | 0 | | |
| Metabolism and nutrition disorders | | | |
| Diabetes mellitus | | | |
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hyperuricaemia | | | |

| | | | |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 0 / 171 (0.00%) | | |
| occurrences (all) | 0 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-------------------|---|
| 18 September 2013 | This protocol is amended to implement advice received from national European Health Authorities, including recommendations to apply a 95% rather than a 90% confidence interval to the primary endpoint and to increase the size of the safety database for continuous treatment with GP2015 in comparison to the reference product. The sample size is increased to 546 randomized patients; the number of study sites is increased accordingly. The re-randomization scheme at week 12 is changed to a ratio of 3:1 instead of 1:1: 75% of patients will continue on their assigned treatment arm (either GP2015 or Enbrel®) whilst 25% will be randomized to receive alternating treatment. The confidence interval is increased to 95%. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported